Navigation Links
Xanodyne Agrees to Withdraw Propoxyphene From the U.S. Market
Date:11/19/2010

SILVER SPRING, Md., Nov. 19, 2010 /PRNewswire-USNewswire/ -- Xanodyne Pharmaceuticals Inc., which makes Darvon and Darvocet, the brand version of the prescription pain medication propoxyphene, has agreed to withdraw the medication from the U.S. market at the request of the U.S. Food and Drug Administration. The FDA has also informed generic manufacturers of Xanodyne's decision and they will be removing their propoxyphene-containing products from the market as well.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The FDA sought market withdrawal of propoxyphene after receiving new clinical data showing that the drug puts patients at risk of potentially serious or even fatal heart rhythm abnormalities. As a result of these data, combined with other information, including new epidemiological data, the agency concluded that the risks of the medication outweigh the benefits.  

"FDA is pleased by Xanodyne's decision to voluntarily remove its products from the U.S. market," said John Jenkins, M.D., director of the Office of New Drugs in the FDA's Center for Drug Evaluation and Research (CDER). "These new heart data significantly alter propoxyphene's risk-benefit profile. The drug's effectiveness in reducing pain is no longer enough to outweigh the drug's serious potential heart risks."

The FDA is advising health care professionals to stop prescribing propoxyphene to their patients, and patients who are currently taking the drug should contact their health care professional as soon as possible to discuss switching to another pain management therapy.

Propoxyphene is an opioid used to treat mild to moderate pain. First approved by the FDA in 1957, propoxyphene is sold by prescription under various names both alone (e.g., Darvon) or in combination with acetaminophen (e.g., Darvocet).

Since 1978, the FDA has received two requests to remove propoxyphene from the market.  Until now, the FDA had concluded that the benefits of propoxyphene for pain relief at recommended doses outweighed the safety risks of the drug.

In January 2009, the FDA held an advisory committee meeting to address the efficacy and safety of propoxyphene. After considering the data submitted with the original drug applications for propoxyphene, as well as subsequent medical literature and postmarketing safety databases, the committee voted 14 to 12 against the continued marketing of propoxyphene products. In making this recommendation, the committee noted that additional information about the drug's cardiac effects would be relevant in weighing its risks and benefits.

In June 2009, the European Medicines Agency (EMEA) recommended that the marketing authorizations for propoxyphene be withdrawn across the European Union. A phased withdrawal of propoxyphene is underway.

In July 2009, the FDA decided to permit continued marketing, but required that a new boxed warning be added to the drug label alerting patients and health care professionals to the risk of a fatal overdose. In addition, the agency required Xanodyne to conduct a new safety study assessing unanswered questions about the effects of propoxyphene on the heart.

The agency now has reviewed the data from that study, which show that, even when taken at recommended doses, propoxyphene causes significant changes to the electrical activity of the heart. These changes, which can be seen on an electrocardiogram (EKG), can increase the risk for serious abnormal heart rhythms that have been linked to serious adverse effects, including sudden death. The available data also indicate that the risk of adverse events for any particular patient (even patients who have taken the drug for many years) is subject to change based on small changes in the health status of the patient, such as dehydration, a change in medications, or decreased kidney function.

"With the new study results, for the first time we now have data showing that the standard therapeutic dose of propoxyphene can be harmful to the heart," said Gerald Dal Pan, M.D., M.H.S., director of the Office of Surveillance and Epidemiology, CDER. "However, long-time users of the drug need to know that these changes to the heart's electrical activity are not cumulative. Once patients stop taking propoxyphene, the risk will go away."

Xanodyne is based in Newport, Ky.

For more information:

Propoxyphene-Containing Products

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm233800.htm

Media Inquiries: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Xanodyne Announces Planned President & CEO Succession
2. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
3. Xanodyne Announces Renewed Focus on Pain Management Market
4. Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
5. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
6. Boston Scientific Agrees to Sell Neurovascular Business to Stryker
7. Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia
8. Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
9. Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws
10. Graymark Healthcare Agrees to Sell Pharmacy Division to Walgreens Creating Pure Play Sleep Apnea Company
11. Fox Insurance Agrees to Pay Delinquent Medicare Part D Claims After Action by Senators Baucus, Grassley, CMS and NCPA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 2017 Revenue Prospects by Product Type (Metered ... and Geography Respiratory Inhalers - our new study reveals ... Inhalers market heading? If you are involved in this sector you ... you the potential revenues streams to 2027, assessing data, trends, opportunities ... ...
(Date:3/29/2017)... 29, 2017 Research and Markets has ... Size & Forecast By Type (Insource IONM, Outsource IONM), By ... to their offering. ... The global Intraoperative Neuromonitoring (IONM) market is ... neuromonitoring market is anticipated to witness significant growth in the ...
(Date:3/29/2017)... -- Research and Markets has announced the addition of ... their offering. ... The global energy-based aesthetic devices market to grow at a CAGR ... Global Energy-Based Aesthetic Devices Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... In the United States alone, up to 36% of primary ... of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are known ... effective treatment options, the San Diego Gamma Knife Center offers a precision-medicine ...
(Date:3/29/2017)... ... ... is the main cause of hay fever in the United States, with an estimated 95 ... May to July each year; with the worst time for sufferers being June and July. ... http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent studies ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sublime Naturals ... "Spice of Life" or "Wonder Spice", it has been used for thousands of years. ... the East," says Heshelow, author of " Turmeric: How to Use it For Your ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, ... southeastern states. Ingredients in HeartBoost, an over the counter heart healthy drink, can ...
(Date:3/29/2017)... ... March 29, 2017 , ... Patients ... in Carnegie, OK, from Dr. Jamie Cameron, with or without a referral. The ... traditional orthodontic treatment. Depending on each patient’s case, treatment with the FASTBRACES system ...
Breaking Medicine News(10 mins):